Eli Lilly & Co

LLY

Equity

ISIN null / Valor 947556

New York Stock Exchange, Inc (2026-01-20)

USD 1,041.29+0.28%

Eli Lilly & Co
UMushroom community rating:

4.42 26 votes No rating yet

NegativeNeutralPositive

About company

Eli Lilly & Co, headquartered in Indianapolis, is a global pharmaceutical company with a significant presence in the healthcare sector. Known for its research, development, and commercialization of pharmaceutical products, Eli Lilly focuses on a wide range of therapeutic areas including but not limited to oncology, diabetes, neurodegeneration, and immunology. The company has recently announced results from a pioneering study of lebrikizumab, a treatment specifically designed for individuals with skin of color suffering from moderate-to-severe atopic dermatitis, also known as eczema. This highlights Eli Lilly's commitment to addressing diverse medical needs and expanding its portfolio to include treatments tailored for specific demographic groups. The company's efforts in innovation and targeted research underscore its role in advancing medical treatments and improving patient outcomes across various disease states.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

37.4%1Y

201%3Y

417%5Y

Performance

40.4%1Y

33.6%3Y

31.4%5Y

Volatility

984419 M

Market cap (USD)

2,484,927

Daily traded volume (Shares)

779.59 / 771.02

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.42

26 votes

Performance:

4.32

Innovation:

4.32

Society:

4.26

Nature:

4.04

Tommaso Nebuloni

United Kingdom, 07 Nov 2025

Strong upside potential in the long-term: Obesity care is forecast to keep expanding, with GLP-1 sales projected around $95–100B by 2030 as global obesity rates rise, creating a long runway.